Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/LIFECORE BIOMEDICAL, INC. \DE\/ SCHEDULE 13D/A

SEC Filing · SCHEDULE 13D/A

LIFECORE BIOMEDICAL, INC. \DE\

LFCRNASDAQEQUITYCurrent

SEC Filing

Filed Jul 2, 2026Accepted Jul 2, 2026, 5:15 PM EDTCIK 1005286Accession 0001193125-26-294951
View company →Permanent SEC source ↗
Share

Company context

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic

Current securities

LFCRNASDAQ · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 5, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 5, 2026
  3. SCHEDULE 13G filingJul 29, 2026
  4. SCHEDULE 13D/A - filed by Legion Partners Asset Management, LLC regarding LIFECORE BIOMEDICAL, INC. \DE\Jul 2, 2026
  5. Regulation FD DisclosureJul 2, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗